An international one year TEMPO trial reports in addition to the usual methotrexate therapy, rheumatoid arthritis patients also benefits from ENBREL* (etanercept), a biological treatment. A report ...
LOS ANGELES, Nov 7 (Reuters) - Early results from an ongoing study showed that people with newly diagnosed rheumatoid arthritis were more likely to reach clinical remission with Amgen Inc and Wyeth's ...
Amsterdam – Rheumatoid arthritis patients who are on standard methotrexate therapy may benefit from the addition of the biologic treatment, ENBREL* (etanercept), according to new data from a one-year, ...
The goals of RA treatment can be achieved within a year of combined therapy with Wyeth’s Enbrel and the standard methotrexate in patients with severe disease who are treated early and these effects ...
Amgen and Pfizer Announce Results From the Largest Completed Clinical Trial of a Biologic Therapy in Adults with Moderately Active RA THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- ...
Amgen and marketing partner Wyeth have been boosted by interim data from a study which shows that a combination of Enbrel and methotrexate is highly effective as a treatment for active early ...
THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...
-- Study Results Provide Further Evidence That Early Treatment of Rheumatoid Arthritis With Enbrel(R) Plus Methotrexate in Moderate to Severe Patients can Stop the Disease From Progressing, and Helps ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A reduced dose of Enbrel in addition to ...
With Pfizer poised to hand off full promotional responsibilities for Enbrel to its partner Amgen, New England Journal of Medicine has published a study suggesting that the $4 billion RA drug may not ...
SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback